Dominga Rogolino

Prof. Dominga Rogolino

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MCMauro Carcelli
Mauro Carcelli
MTMatteo Tegoni
Matteo Tegoni
JBJennifer Bartoli
Jennifer Bartoli
CMCristina Marzano
Cristina Marzano
GPGiorgio Pelosi
Giorgio Pelosi
Valentina GandinValentina Gandin
Valentina Gandin

18 October 2005 in Organometallics
Verified
Journal Article
Closed access
PPPaolo Pelagatti
Paolo Pelagatti
MCMauro Carcelli
Mauro Carcelli
FCFrancesca Calbiani
Francesca Calbiani
CCClaudio Cassi
Claudio Cassi
LELisa Elviri
Lisa Elviri
DRDominga Rogolino
Dominga Rogolino

20 June 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMario Sechi
Mario Sechi
ABAlessia Bacchi
Alessia Bacchi
MCMauro Carcelli
Mauro Carcelli
CCCarlotta Compari
Carlotta Compari
EDElenia Duce
Elenia Duce
NNNouri Neamati
Nouri Neamati

1 February 2005 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
ABAlessia Bacchi
Alessia Bacchi
MCMauro Carcelli
Mauro Carcelli
PPPaolo Pelagatti
Paolo Pelagatti
GPG. Pelizzi
G. Pelizzi
M Carmen Rodríguez ArgüellesM Carmen Rodríguez Argüelles
M Carmen Rodríguez Argüelles
FZF. Zani
F. Zani

11 August 2016 in Scientific Reports
Verified
Journal Article
Open access
MCMauro Carcelli
Mauro Carcelli
DRDominga Rogolino
Dominga Rogolino
AGAnna Gatti
Anna Gatti
LLLaura De Luca
Laura De Luca
MSMario Sechi
Mario Sechi
LNLieve Naesens
Lieve Naesens
Influenza virus PA endonuclease has recently emerged as an attractive target for the development of novel antiviral therapeutics. This is an enzyme with divalent metal ion(s) (Mg2+ or Mn2+) in its catalytic site: chelation of these metal cofactors is an attractive strategy to inhibit enzymatic activity. Here we report the activity of a series of N-acylhydrazones in an enzymatic assay with PA-Nter endonuclease, as well as in cell-based influenza vRNP reconstitution and virus yield assays. Several N-acylhydrazones were found to have promising anti-influenza activity in the low micromolar concentration range and good selectivity. Computational docking studies are carried on to investigate the key features that determine inhibition of the endonuclease enzyme by N-acylhydrazones. Moreover, we here describe the crystal structure of PA-Nter in complex with one of the most active inhibitors, revealing its interactions within the protein’s active site.

1 October 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ASAnnelies Stevaert
Annelies Stevaert
Roberto Nico DallocchioRoberto Nico Dallocchio
Roberto Nico Dallocchio
Alessandro DessìAlessandro Dessì
Alessandro Dessì
NPNicolino Pala
Nicolino Pala
DRDominga Rogolino
Dominga Rogolino
LNLieve Naesens
Lieve Naesens
The influenza virus PA endonuclease, which cleaves capped host pre-mRNAs to initiate synthesis of viral mRNA, is a prime target for antiviral therapy. The diketo acid compound L-742,001 was previously identified as a potent inhibitor of the influenza virus endonuclease reaction, but information on its precise binding mode to PA or potential resistance profile is limited. Computer-assisted docking of L-742,001 into the crystal structure of inhibitor-free N-terminal PA (PA-Nter) indicated a binding orientation distinct from that seen in a recent crystallographic study with L-742,001-bound PA-Nter (R. M. DuBois et al., PLoS Pathog. 8:e1002830, 2012). A comprehensive mutational analysis was performed to determine which amino acid changes within the catalytic center of PA or its surrounding hydrophobic pockets alter the antiviral sensitivity to L-742,001 in cell culture. Marked (up to 20-fold) resistance to L-742,001 was observed for the H41A, I120T, and G81F/V/T mutant forms of PA. Two- to 3-fold resistance was seen for the T20A, L42T, and V122T mutants, and the R124Q and Y130A mutants were 3-fold more sensitive to L-742,001. Several mutations situated at noncatalytic sites in PA had no or only marginal impact on the enzymatic functionality of viral ribonucleoprotein complexes reconstituted in cell culture, consistent with the less conserved nature of these PA residues. Our data provide relevant insights into the binding mode of L-742,001 in the PA endonuclease active site. In addition, we predict some potential resistance sites that should be taken into account during optimization of PA endonuclease inhibitors toward tight binding in any of the hydrophobic pockets surrounding the catalytic center of the enzyme.